Objective  To conduct a multidimensional and multi-level evaluation of the comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes mellitus.

Methods  Based on the National Essential Medicines List (2018 Edition), dapagliflozin was selected as the control. A comprehensive clinical evaluation index system was established through literature review, focus group interviews and in-depth expert interviews, encompassing six dimensions: safety, efficacy, economy, suitability, innovation, and accessibility. The Delphi method and hierarchical direct weighting method were used to screen indicators and determine their weights. Evidence for each indicator was collected and integrated both qualitatively and quantitatively through literature research, real-world studies, and pharmacoeconomic evaluations. Experts scored the indicators based on the collected evidence, and a total score for the comprehensive clinical evaluation of empagliflozin was calculated by combining these scores with indicator weights, followed by a comparative analysis with dapagliflozin.

Results  A comprehensive clinical evaluation of empagliflozin in the treatment of type 2 diabetes mellitus was successfully established, consisting of 6 primary indicators, 14 secondary indicators, and 41 tertiary indicators. The overall evaluation score for empagliflozin was 90.35, and 89.47 for dapagliflozin.

Conclusion  The comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes mellitus is slightly higher than that of dapagliflozin. This finding can serve as a reference for rational clinical drug use and related decision-making.

1.Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109-119. DOI: 10.1016/j.diabres.2021.109119．

2.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 国际内分泌代谢杂志, 2021, 41(5): 482-548. [Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. International Journal of Endocrinology and Metabolism, 2021, 41(5): 482-548.] DOI: 10.3760/cma.j.cn121383-20210825-08063.

3.National Institute for Health and Care Excellence. Type 2 diabetes in adults: management [R/OL]. (2022-06-29) [2022-11-20]. https://www.nice.org.uk/guidance/ng28.

4.国家卫生健康委办公厅. 国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知: 国卫办药政发〔2021〕16号[EB/OL]. (2021-07-28) [2024-03-30]. http://www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415-d84adf3797b0f4869.shtml.

5.张永泽, 李树祥, 杨庆. 应用德尔菲法构建临床药师核心能力评价标准[J]. 中国药房, 2019, 30(6): 730-734. [Zhang YZ, Li SX, Yang Q. Construction of core competency evaluation standards for clinical pharmacists by Delphi method[J]. China Pharmacy, 2019, 30(6): 730-734.] DOI: 10.6039/j.issn.1001-0408. 2019.06.03.

6.赵瑞玲, 黄亚云, 张夏丽, 等. 儿童退热药布洛芬制剂临床综合评价指标体系的构建[J]. 中国医院药学杂志, 2022, 42(7): 758-761. [Zhao RL, Huang YY, Zhang XL, et al. Construction of clinical comprehensive evaluation index system for antipyretic drug ibuprofen preparations in children[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(7): 758-761.] DOI: 10.13286/j.1001-5213.2022.07.18.

7.刘秀娜. 我国护理学博士研究生教育培养目标的探索性研究 [D]. 重庆: 第三军医大学, 2012.

8.孙凤, 杨智荣, 张天嵩, 等. 网络Meta分析研究进展系列之一: 概述[J]. 中国循证心血管医学杂志, 2020, 12(6): 644-650. [Sun F, Yang ZR, Zhang TS, et al. Advances in methodology of network Meta-analysis(1): overview[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2020, 12(6): 644-650.] DOI: 10.3969/j.issn.1674-4055.2020.06.02.

9.文志勇, 郭嘉豪, 杨雪明, 等. 仿制与原研维格列汀片治疗2型糖尿病有效性和安全性比较的真实世界研究[J]. 药物不良反应杂志, 2023, 25(3): 138-144. [Wen ZY, Guo JH, Yang XM, et al. Comparison of efficacy and safety of generic versus original vildagliptin tablets in type 2 diabetes mellitus: a real world study[J]. Adverse Drug Reactions Journal, 2023, 25(3): 138-144.] DOI: 10.3760/cma.j.cn114015-20221109-01041.

10.薛青霞, 张会苑, 慕升君, 等. 恩格列净与达格列净治疗成人2型糖尿病的有效性和安全性比较[J]. 中国医院用药评价与分析, 2025, 25(6): 665-668, 674. [Xue QX, Zhang HY, Mu SJ, et al. Comparison on efficacy and safety of empagliflozin and dapagliflozin in the treatment of patients with type 2 diabetes mellitus[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2025, 25(6): 665-668, 674.] DOI: 10.14009/j.issn.1672-2124.2025.06.005.

11.Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial[J]. Diabetes Care, 2013, 36(11): 3396-3404. DOI: 10.2337/dc12-2673.

12.吴晶, 贺小宁, 刘艳辉. 中国2型糖尿病患者应用门冬胰岛素30与甘精胰岛素的成本-效果分析[J]. 中国药学杂志, 2016, 51(3): 242-247. [Wu J, He XN, Liu YH. Cost-eEffectiveness analysis of insulin aspart 30 versus insulin glargine in patients with type 2 diabetes in China[J]. Chinese Pharmaceutical Journal, 2016, 51(3): 242-247.] DOI: 10.11669/cpj.2016.03.021.

13.Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network Meta-analysis[J]. BMJ Open, 2016, 6(2): e009417. DOI: 10.1136/bmjopen-2015-009417.

14.Salem A, Men P, Ramos M, et al. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with type 2 diabetes in China[J]. J Comp Eff Res, 2021, 10(6): 469-480. DOI: 10.2217/cer-2020-0284.

15.Ebrahimi P, Soleimani H, Mahalleh M, et al. Cardiovascular outcomes of SGLT-2 inhibitors' subtypes in type 2 diabetes; an updated systematic review and Meta-analysis of randomized controlled trials[J]. J Diabetes Metab Disord, 2025, 24(1): 47. DOI: 10.1007/s40200-024-01545-w.

16.Teng Y, Fan X, Yu R, et al. Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network Meta-analysis[J]. BMC Endocr Disord, 2024, 24(1): 278. DOI: 10.1186/s12902-024-01805-z.

17.Pinto LC, Rados DV, Remonti LR, et al. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and Meta-analysis[J]. Arch Endocrinol Metab, 2022, 66(1): 68-76. DOI: 10.20945/2359-3997000000440.

18.Ghosal S, Sinha B. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network Meta-analysis-based scoring[J]. Front Endocrinol (Lausanne), 2023, 14: 1168755. DOI: 10.3389/fendo.2023.1168755.

19.Chen JY, Pan HC, Shiao CC, et al. Impact of SGLT2 inhibitors on patient outcomes: a network Meta-analysis[J]. Cardiovasc Diabetol, 2023, 22(1): 290. DOI: 10.1186/s12933-023-02035-8.

20.Tian L, Ai S, Zheng H, et al.Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: a system review and network Meta-analysis[J]. Front Pharmacol, 2022, 13: 986186. DOI: 10.3389/fphar.2022.986186.

21.Jiang Y, Yang P, Fu L, et al. Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network Meta-analysis of randomized controlled trials[J]. Front Endocrinol (Lausanne), 2022, 13: 802992. DOI: 10.3389/fendo.2022.802992.

22.Ahmad Y, Madhavan MV, Stone GW, et al. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and Meta-analysis of randomized trials[J]. Eur Heart J Qual Care Clin Outcomes, 2022, 8(4): 383-390. DOI: 10.1093/ehjqcco/qcab072.

23.王润青, 王谦, 廖健雄. SGLT2抑制剂对2型糖尿病患者心血管结局影响的网状Meta分析[J]. 临床荟萃, 2022, 37(12): 1061-1073. [Wang RQ, Wang Q, Liao JX. A network Meta-analysis of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes[J]. Clinical Focus, 2022, 37(12): 1061-1073.] DOI: 10.3969/j.issn.1004-583X.2022.12.001.

24.Mahboob E, Samad MA, Shafiq A, et al. Meta-analysis of cardiovascular efficacy of empagliflozin versus dapagliflozin in type 2 diabetes: unveiling key insights[J/OL]. Cardiol Rev, [2025-09-13]. DOI: 10.1097/CRD.0000000000000916.

25.国家药品监督管理局. 美国警告钠-葡萄糖共同转运体抑制剂与血液中酸过多和严重尿路感染风险[EB/OL]. (2016-03-04) [2024-03-28]. https://www.nmpa.gov.cn/directory/web/nmpa//xxgk/yjjsh/ywjjkx/20160304101901550.html.

26.国家药品监督管理局. 美国警告SGLT2降糖药的罕见严重的生殖区感染风险[EB/OL]. (2018-10-19) [2024-03-30]. https://www.nmpa.gov.cn/directory/web/nmpa///////xxgk/yjjsh/ywjjkx/20181019171301688.html.

27.国家药品监督管理局. 英国警示SGLT2抑制剂的生殖器或会阴区坏死性筋膜炎风险[EB/OL]. (2019-04-24) [2025-04-01]. 错误!超链接引用无效。.

28.国家药品监督管理局. 欧盟拟采取措施降低SGLT2抑制剂的酮症酸中毒风险[EB/OL]. (2016-04-20) [2024-03-25]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20160420163801199.html.

29.国家药品监督管理局. 欧盟警告SGLT2抑制剂下肢截肢风险[EB/OL]. (2017-07-14) [2024-03-18]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20170714161901164.html.

30.国家药品监督管理局. WHO关注列净类降糖药与生殖器瘙痒风险[EB/OL]. (2017-09-28) [2024-03-26]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ywjjkx/20170928155401472.html.

31.国家药品监督管理局. 加拿大评估SGLT2抑制剂的胰腺炎风险[EB/OL]. (2018-09-04) [2024-03-28]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20180904112301131.html.

32.Chen L, Xue Q, Yan C, et al. Comparative safety of different recommended doses of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network Meta-analysis of randomized clinical trials[J]. Front Endocrinol (Lausanne), 2023, 14: 1256548. DOI: 10.3389/fendo.2023.1256548.

33.郭婷婷, 朱丽. 恩格列净致低血压1例[J]. 中南药学, 2022, 20(3): 715-716. DOI: 10.7539/j.issn.1672-2981.2022.03.044.

34.刘永红, 陈晓平, 帅瑛. 恩格列净致皮肤过敏反应[J]. 药物不良反应杂志, 2021, 23(9): 493-494. [Liu YH, Chen XP, Shuai Y. Skin allergic reaction induced by empagliflozin[J]. Adverse Drug Reactions Journal, 2021, 23(9): 493-494.] DOI: 10.3760/cma.j.cn1140152021010500013.

35.蔡俊, 纪立伟. 恩格列净片致心悸1例[J]. 中国药物警戒, 2019, 16(8): 506-507. [Cai J, Ji LW. One case of palpitation induced by empagliflozin tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 506-507.] DOI: 10.19803/j.1672-8629.2019.08.009.

36.Alhemeiri M, Alseddeeqi E. Euglycemic diabetic ketoacidosis after discontinuing SGLT2 inhibitor[J]. Case Rep Endocrinol, 2022: 4101975. DOI: 10.1155/2022/4101975.

37.Foster P, Jha P, Pandit S. Empagliflozin-induced pancreatitis: a case report pattern[J]. Cureus, 2022, 14(5): e25189. DOI: 10.7759/cureus.25189.

38.王秀丽, 段磊, 胡宝祥, 等. 达格列净致中枢神经系统不良反应1例[J]. 中华急诊医学杂志, 2022, 31(5): 699-700. [Wang XL, Duan L, Hu BX, et al. A case of central nervous system adverse reaction caused by dagliflozin[J]. Chinese Journal of Emergency Medicine, 2022, 31(5): 699-700.] DOI: 10.3760/cma.j.issn.1671-0282.2022.05.025.

39.卢姗, 李立, 王声祥, 等. 达格列净致急性肾损伤1例 [J]. 中南药学, 2022, 20(3): 712-714. DOI: 10.7539/j.issn.1672-2981. 2022.03.043.

40.曾艳, 马春玲. 达格列净致视网膜出血1例[J]. 药物流行病学杂志, 2022, 31(2): 143-144. DOI: 10.19960/j.cnki.issn1005-0698.2022.02.016.

41.巴天皓, 张静, 刘健, 等. 达格列净致直立性低血压一例报道[J]. 中国糖尿病杂志, 2021, 29(12): 930-932. [Ba TH, Zhang J, Liu J, et al. Orthostatic hypotension induced by dapagliflozin: a case report[J]. Chinese Journal of Diabetes, 2021, 29(12): 930-932.] DOI: 10.3969/j.issn.1006-6187.2021.12.009.

42.Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, et al. Dapagliflozin-induced acute pancreatitis: a case report and review of literature[J]. Case Rep Endocrinol, 2020, 14(2020): 6724504. DOI: 10.1155/2020/6724504.

43.Luo X, Ji R, Lu W, et al. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient who underwent surgery for pancreatic carcinoma: a case report[J]. Front Surg, 2022, 9: 769041. DOI: 10.3389/fsurg.2022.769041.

44.Elbeddini A, Tayefehchamani Y, Davey M, et al. Fournier's gangrene with dapagliflozin in a rural hospital: a case report[J]. BMJ Case Rep, 2021, 14(2): e237784. DOI: 10.1136/bcr-2020-237784.

45.El Masri D, Jamil Y, Eid Fares J. Sodium-glucose co-transporter protein 2 inhibitors induced hypercalcemia: a case series and literature review[J]. AACE Clin Case Rep, 2021, 8(1): 30-33. DOI: 10.1016/j.aace.2021.07.002.

46.Mattis DM, Limova M, Mully T. Dapagliflozin-induced sweet syndrome[J]. Cutis, 2019, 104(2): E22-E24. https://pubmed.ncbi.nlm.nih.gov/31603973/.

47.Levine JA, Ann Lo A, Wallia A, et al. Dapagliflozin-induced acute-on-chronic liver injury[J]. ACG Case Rep J, 2016, 3(4): e169. DOI: 10.14309/crj.2016.142.

48.Senoo M, Tone A, Imai Y, et al. Marked hypertriglyceridemia in a patient with type 2 diabetes receiving SGLT2 inhibitors[J]. Acta Med Okayama, 2021, 75(1): 103-107. DOI: 10.18926/AMO/61441.

49.Stella M, Biassoni E, Fiorillo C, et al. A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors[J]. Neurol Sci, 2022, 43(7): 4567-4570. DOI: 10.1007/s10072-022-06046-3.

50.陈诚, 邓斌. 恩格列净联合利格列汀治疗2型糖尿病的临床研究[J]. 药物评价研究, 2020, 43(5): 880-884. [Chen C, Deng B. Clinical study on empagliflozin combined with linagliptin in treatment of type 2 diabetes[J]. Drug Evaluation Research, 2020, 43(5): 880-884.] DOI: 10.7501/i.issn.1674-6376.2020.05.015.

51.张铭, 张娜娜, 余信, 等. 达格列净对大鼠心肌缺血再灌注损伤保护的实验研究[J]. 陕西医学杂志, 2022, 51(7): 795-798. [Zhang M, Zhang NN, Yu X, et al. Protective effect of dapagliflozin on myocardial ischemia-reperfusion injury in rats[J]. Shaanxi Medical Journal, 2022, 51(7): 795-798.] DOI: 10.3969/j.issn.1000-7377.2022.07.006.

52.赵菲菲, 刘新林, 康静, 等. 达格列净对新诊断2型糖尿病患者血脂代谢的影响[J]. 中国实用医药, 2022, 17(14): 21-24. [Zhao FF, Liu XL, Kang J, et al. Effect of dapagliflozin on lipid metabolism in newly diagnosed type 2 diabetes mellitus patients[J]. Chinese Practical Medicine, 2022, 17(14): 21-24.] DOI: 10.14163/j.cnki.11-5547/r.2022.14.005.

53.中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6): 369-381. [Chinese Diabetes Society, Chinese Society of Endocrinology. Expert consensus on glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease[J]. Chinese Journal of Diabetes Mellitus, 2020, 12(6): 369-381.] DOI: 10.3760/cma.j.cn115791-20200419-00233.

54.Ko SH, Hur KY, Rhee SY, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association[J]. Korean J Intern Med, 2017, 32(6): 947-958. DOI: 10.3904/kjim.2017.298.

55.Oh TJ, Moon JY, Hur KY, et al. Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement[J]. Diabetes Metab J, 2020, 44(4): 489-497. DOI: 10.4093/dmj.2020.0172.

56.Seidu S, Cos X, Brunton S, et al. A disease state approach to the pharmacological management of type 2 diabetes in primary care: aposition statement by Primary Care Diabetes Europe[J]. Prim Care Diabetes, 2021, 15(1): 31-51. DOI: 10.1016/j.pcd.2020.05.004.

57.Hur KY, Moon MK, Park JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association[J]. Diabetes Metab J, 2021, 45(4): 461-481. DOI: 10.4093/dmj.2021.0156.

58.Mannucci E, Candido R, Delle Monache L, et al. Italian guidelines for the treatment of type 2 diabetes[J]. Nutr Metab Cardiovasc Dis, 2022, 32(4): 770-814. DOI: 10.1016/j.numecd.2022.01.027.

59.石剑. SGLT-2抑制剂类糖尿病药物的研究进展和专利分析 [J]. 河南科技, 2019(27): 8-14. DOI: 10.3969/j.issn.1003-5168. 2019.27.003.

60.侯琴, 周琼, 赵春霖, 等. 糖尿病药物—SGLT-2抑制剂专利技术分析[J]. 药学研究, 2019, 38(5): 303-306. [Hou Q, Zhou Q, Zhao CL, et al. Analysis of patent technology of antidiabetics—SGLT-2 inhibitors[J]. Journal of Pharmaceutical Research, 2019, 38(5): 303-306.] DOI: 10.13506/j.cnki.jpr.2019.05.014.

61.北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志（电子版）, 2020, 12(8): 1-73. DOI: 10.12037/YXQY.2020.08-01.

62.国家统计局. 中华人民共和国2021年国民经济和社会发展统计公报[R/OL]. (2022-02-28) [2023-05-10]. https://www.gov.cn/xinwen/2022-02/28/content_5676015.htm.

63.上海阳光医药采购网. 关于公布全国药品集中采购中选结果的通知[EB/OL]. (2021-02-08) [2023-05-10]. https://www.smpaa.cn/gjsdcg/2023/04/11/11968.shtml.

64.国家卫生健康委员会，国家中医药管理局. 关于印发国家基本药物目录（2018年版）的通知[EB/OL]. (2018-11-01) [2023-05-10]. https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435470.htm.

65.梅佳, 吴美璇, 胡泽林, 等. 糖尿病患者视网膜病变危险因素的Meta分析[J]. 数理医药学杂志, 2024, 37(5): 360-370. [Mei J, Wu MX, Hu ZL, et al. The risk factors of retinopathy in diabetes patients: a Meta-analysis[J]. Journal of Mathematical Medicine, 2024, 37(5): 360-370.] DOI: 10.12731/j.issn.1004-4337. 202401075.